InvestorsHub Logo
Followers 163
Posts 12880
Boards Moderated 1
Alias Born 01/26/2016

Re: edwick709 post# 53651

Saturday, 02/13/2016 11:00:33 PM

Saturday, February 13, 2016 11:00:33 PM

Post# of 699678
edwick709,

I will be glad to read through your suggested material. Good to have doctors and professors on board here and your contributions are much appreciated. I have no such credentials but strong interest has kept me glued to oncology related research. Historical cycles tell me we are nearing multiple scientific breakthroughs.

Steven brings great research ability to the table but tends to arrive at conclusions prematurely because of missing analysis and understanding of biologic processes. For example, I lamented the fact that spacing of Direct injections were separated by too much time. This was explained by NWBO as a safety related concession for Phase 1. FDA also slowed the trial down to assess safety related issues as first in man. This did not appear necessary based on historical evidence but probably acted as an insurance policy for FDA and is part of a fairly consistent pattern they have used in the past.

Spacing of injections and number of injections is critical to the immune response build up and immunosuppressive response to the treatment. I explained this to Steven before on a Seeking Alpha article. He conceded this point reluctantly by saying that this might offer a little more hope to eventually seeing clinical responses based at least to some degree on recist crteria. My main point was that dendritic cells on average only live a few weeks and educated Direct DCs will not last even that long in the tumor microenvironment as hypoxia causes lingering DCs to become circulatory DCs which leave the site. Some D Cs will pick up antigens and move to the lymph to educate T-cells while those that don't are still needed to regulate the tumor environment with proper signaling activity. If disregulation occurs too soon the immune response can not achieve sufficient strength even if immune memory with T and B cells has already begun to have an effect. This is a critical process to understand and why injection spacing, number and number of cells in each injection is so important. They need to get this right before they can reveal Direct's greater potential.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News